Healthcare >> CEO Interviews >> May 13, 2003
DR. GINGER JOHNSON is a Senior Consultant at Defined Health. With
a career that includes positions in basic and applied scientific
research, private equity investing and corporate development, Dr.
Johnson has a unique understanding of the issues critical to the
success of a growing biotechnology venture and the proven ability
to identify the commercial viability of emerging technologies and
trends in the life science industry. She participates in and
manages core assessment and strategic consulting projects, with a
special emphasis on CNS-associated therapeutic categories. Dr.
Johnson was Vice President for Corporate Development team at
Skila, Inc., where she identified and executed strategic
partnerships and worked in conjunction with Skila's executive
team to define their corporate strategy. Dr. Johnson joined Skila
from Chase Capital Partners (now JP Morgan Partners), a global
private equity investment firm. She was the Director of Life
Science Research. Prior to CCP, Dr. Johnson was the Associate
Director of the innovative graduate program at Northwestern
University that combines the science and business of
biotechnology. She has published 14 peer-reviewed publications,
presented over 20 abstracts, and is an inventor on several
patents. Dr. Johnson received a BS in Molecular Biology from the
University of Tennessee, a PhD in Genetics from George Washington
University, and has completed graduate studies at the J.L.
Kellogg Graduate School of Management at Northwestern University. Profile
Dr. Johnson: Defined Health is a 20-year-old business development
consultancy, and our clients are primarily pharmaceutical,
biotechnology
